TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23032060
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion at three progressively higher rates (approximately 150, 350, and 700 pmol/liter) during hyperglycemia (glucose maintained at approximately 9 mmol/liter)
Study: 20547942
Drug: Topical voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical voriconazole (in patients with baseline BSCVA of 20/40 to 20/400)
Study: 12080437
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Mediterranean diet and leisure time physical activity
Study: 1771224
Drug: Atenolol (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (75 mg)
Study: 6787141
Drug: Parenteral hyperalimentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral hyperalimentation fluids
Study: 30579806
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 mg every 2 weeks added to rosuvastatin 10 mg/day
Study: 30579806
Drug: Standard-of-care arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care arm (rosuvastatin 10 mg/day, with initiation and/or dose adjustment of non-statin lipid-lowering to achieve an LDL-C target of <70 mg/dL)
Study: 21419745
Drug: 7 mg/d
Normalized name: nicotine 7 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 mg/d MK-0736
Study: 19263464
Drug: Active antidepressant
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active antidepressant groups
Study: 19263464
Drug: Treatment allocation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment allocation
Study: 17723086
Drug: Vasodilatory antihypertensives
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasodilatory antihypertensives (renin-angiotensin-aldosterone system inhibitors and calcium channel blockers)
Study: 9885116
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no Factor XIII administration)
Study: 7930743
Drug: Single-dose artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single-dose artesunate (4 mg/kg) plus mefloquine (25 mg of base/kg)
Study: 7930743
Drug: Three days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three days of artesunate (total dose, 10 mg/kg) plus mefloquine (25 mg/kg)
Study: 2124724
Drug: 400-micrograms misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400-micrograms misoprostol tablets twice daily
Study: 426986
Drug: Droperidol 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.25 mg kg‐1
Study: 31164153
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without the orthosis
Study: 25872390
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (nepafenac and dexamethasone)
Study: 15497671
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (Ecrox) 25 mg rofecoxib tablet
Study: 15497671
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (originator product) 25 mg rofecoxib tablet
Study: 23902673
Drug: Lupin protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupin protein isolate (LPI) 25 g/d
Study: 21715698
Drug: Atorvastatin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin therapy (3 months)
Study: 21715698
Drug: Acute L-ascorbate
Normalized name: L-Ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute L-ascorbate alone
Study: 21715698
Drug: L-ascorbate combined
Normalized name: L-Ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-ascorbate combined with arginase inhibition
Study: 21715698
Drug: Ascorbate alone
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbate alone post-atorvastatin
Study: 21715698
Drug: Ascorbate combined
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbate combined with arginase inhibition post-atorvastatin
Study: 16703434
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (2 mg/kg of bupivacaine in 200 ml of normal saline before creation of pneumoperitoneum)
Study: 16703434
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (2 mg/kg of bupivacaine in 200 ml of normal saline after creation of pneumoperitoneum)
Study: 16703434
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (200 ml of normal saline before creation of pneumoperitoneum)
Study: 16703434
Drug: Group D
Normalized name: Prostaglandin group D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D (200 ml of normal saline after creation of pneumoperitoneum)
Study: 10906914
Drug: Comprehensive massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive massage therapy (n = 25)
Study: 10906914
Drug: Sham laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham laser therapy (n = 26)
Study: 9217890
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (3.5 mU/min) for 180 min in protocol I
Study: 9217890
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (100 mU/min) in hand veins in protocol III
Study: 9217890
Drug: Noradrenaline infusion
Normalized name: noradrenaline hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline infusion (0.025, 0.01 and 0.4 microgram/min) at baseline, 90 and 180 min after insulin in protocol I
Study: 9217890
Drug: Noradrenaline infusion
Normalized name: noradrenaline hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline infusion (1.7-55 ng/min) at baseline and at 90 and 180 min in protocol II
Study: 8377448
Drug: Modified BFM-protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified BFM-protocol (ALL REZ I/88) with alternating courses of polychemotherapy including intermediate dose methotrexate (1 g/m2 in 36 hours) and maintenance treatment with daily oral thioguanine and biweekly IV MTX.
Study: 3017033
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II (AII) infusion (5 ng/kg/min)
Study: 3017033
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II (AII) infusion (5 ng/kg/min) with o-CRH injection (100 micrograms)
Study: 3017033
Drug: Sham infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham infusion with o-CRH injection (100 micrograms)
Study: 31810893
Drug: Salvage radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage radiation therapy (sRT)
Study: 20163872
Drug: Laser-induced chorioretinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser-induced chorioretinal venous anastomosis (L-CRA)
Study: 14566347
Drug: Pyridoxine‐metoclopramide combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine‐metoclopramide combination therapy
Study: 8558221
Drug: Docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 100 mg/m2 administered over 1 hour every 21 days
Study: 1992912
Drug: Beta-interferon (IFN)
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-interferon (IFN) therapy
Study: 6441010
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of intravenous metoclopramide administered 10 min prior to nasal insertion of a weighed feeding tube
Study: 31670697
Drug: Noradrenaline administration
Normalized name: noradrenaline hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline administration
Study: 30720004
Drug: SignaturePFS-CG (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: SignaturePFS-CG (combination of clinical factors and COX-2/C-MET/KRAS expression status)
Study: 30720004
Drug: SignatureOS-CG (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: SignatureOS-CG (combination of clinical factors and COX-2/C-MET/KRAS expression status)
Study: 25182660
Drug: Adjunctive dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive dipyridamole 75 mg twice daily
Study: 25182660
Drug: Double-dose clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose clopidogrel 150 mg daily
Study: 22596208
Drug: Memantine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (10 mg)
Study: 18973887
Drug: Micro‐TESE (microdissection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro‐TESE (microdissection testicular sperm extraction) followed by intracytoplasmic sperm injection
Study: 16799799
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 500 microg twice daily for 12 months
Study: 2664817
Drug: Augmentin (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentin (1.2 g intravenously 3-times daily for a mean of 6.6 days, then 375 mg orally for a further 6.4 days)
Study: 2664817
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (1 g cefazoline intravenously 4-times daily plus 500 mg metronidazole intravenously 3-times daily for 7 days, then 500 mg cefadroxil orally 4-times daily for a mean of 6.6 days)
Study: 29275583
Drug: Oxycodone (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (0.2 mg/kg) combined with dexmedetomidine (loading dose of 0.5 μg/kg for 10 minutes and continuous infusion of 0.2 μg·kg(‐1)·h(‐1))
Study: 29275583
Drug: Fentanyl (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (2 μg/kg) combined with dexmedetomidine
Study: 21701083
Drug: EPA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA plus statin (1,800 mg/day)
Study: 16930364
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba (160 mg daily dose)
Study: 16930364
Drug: donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: donepezil (5 mg daily dose)
Study: 15468547
Drug: Trasylol (T)
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trasylol (T) 6 mln KIU administered from patient's admission to surgery room until skin incision, plus 2 mln KIU from surgical approach to beginning of AC, added to ACA.
Study: 15468547
Drug: Trasylol (T)
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trasylol (T) 3 mln KIU administered similarly to group 1 but not added to ACA.
Study: 9144689
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m2 and epirubicin 60 mg/m2 (Group A)
Study: 9144689
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m2 and epirubicin 90 mg/m2 (Group B)
Study: 8175327
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (positive pressure ventilation and supportive care)
Study: 28485264
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g NWT-03
Study: 28485264
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g NWT-03
Study: 25472864
Drug: Isotonic intravenous
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotonic intravenous fluid containing 140 mmol/L of sodium (Na140)
Study: 25472864
Drug: Hypotonic fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotonic fluid containing 77 mmol/L of sodium (Na77)
Study: 23744959
Drug: 0.75 mg·kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg·kg(‐1) lidocaine
Study: 23744959
Drug: 1.5 mg·kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg·kg(‐1) lidocaine
Study: 16316789
Drug: Buprenorphine (new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (new formulation)
Study: 1490923
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B mixed with Intralipid (0.7‐1 mg/kg/day)
Study: 1490923
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B in 5% dextrose (0.7‐1 mg/kg/day)
Study: 3899676
Drug: Diazepam (DZ)
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazepam (DZ) 10 mg
Study: 3899676
Drug: Lorazepam (LZ)
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorazepam (LZ) 2.5 mg
Study: 3899676
Drug: Alcohol 1
Normalized name: benzyl alcohol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol 1 g/kg
Study: 29774768
Drug: Boswellia serrata
Normalized name: Boswellia Serrata
DrugBank: Indian frankincense (DB14275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boswellia serrata gum resin (250 mg twice daily for 8 weeks)
Study: 29774768
Drug: Placebo (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (250 mg twice daily for 8 weeks)
Study: 24307259
Drug: Willingness to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Willingness to accept limits on coverage for expensive drugs and procedures
Study: 24307259
Drug: Agreement with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agreement with limiting coverage for expensive drugs and procedures
Study: 20732849
Drug: Calcipotriol/hydrocortisone combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol/hydrocortisone combination ointment (calcipotriol 25 mcg/g or 50 mcg/g combined with hydrocortisone 10 mg/g)
Study: 20732849
Drug: Calcipotriol alone
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol alone (25 mcg/g or 50 mcg/g)
Study: 20732849
Drug: Calcipotriol/hydrocortisone combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol/hydrocortisone combination ointment
Study: 10983060
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity laser therapy; duration not specified.
Study: 7551780
Drug: Peppermint oil
Normalized name: Peppermint Oil
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peppermint oil mixed with barium preparation
Study: 7551780
Drug: Standard barium
Normalized name: barium
DrugBank: Barium (DB12481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard barium suspension
Study: 2181841
Drug: Labetalol (275
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (275 +/- 29 mg)
Study: 31138136
Drug: Calcifediol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcifediol (10 μg per day)
Study: 19397534
Drug: α-adrenoceptor agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-adrenoceptor agonists (specifically midodrine)
Study: 10773855
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg Linomide
Study: 10773855
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Linomide
Study: 24385283
Drug: Intravenous 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 200 mg gemifloxacin
Study: 24385283
Drug: Oral 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 320 mg gemifloxacin
Study: 25439595
Drug: sham/0.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: sham/0.5 mg
Study: 20629022
Drug: Pyridoxine 100
Normalized name: pyridoxine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine 100 mg twice daily (Group A)
Study: 15701909
Drug: Ximelagatran, 36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran, 36 mg twice daily for 6 months
Study: 15701909
Drug: Enoxaparin/warfarin (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin/warfarin (subcutaneous enoxaparin, 1 mg/kg twice daily for 5 to 20 days followed by warfarin)
Study: 2019751
Drug: Avian-human (ah)
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Avian-human (ah) influenza A/Kawasaki/9/86 reassortant vaccine, 100 HID50
Study: 2019751
Drug: Cold-adapted (ca)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-adapted (ca) influenza A/Kawasaki/9/86 reassortant vaccine
Study: 2019751
Drug: Avian-human (ah)
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Avian-human (ah) influenza A/Kawasaki/9/86 reassortant vaccine
Study: 31693564
Drug: Microdrop blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microdrop blood transfusion set at 10 mL/h
Study: 31693564
Drug: Macrodrop blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macrodrop blood transfusion set at 10 mL/h
Study: 31693564
Drug: Microdrop blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microdrop blood transfusion set at 100 mL/h
Study: 31693564
Drug: Macrodrop blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macrodrop blood transfusion set at 100 mL/h
Study: 28162990
Drug: Psychiatric eConsults
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychiatric eConsults (Treatment group)
Study: 24623069
Drug: Visual inspection
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visual inspection of returned empty gel applicators
Study: 19208978
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of HIV-TB co-infection
Study: 16291408
Drug: Efalizumab 1
Normalized name: efalizumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab 1 or 2 mg/kg SC weekly for 12 weeks
Study: 16291408
Drug: Efalizumab extended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab extended therapy (up to 24 weeks)
Study: 16291408
Drug: Efalizumab continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab continuous therapy (up to 108 weeks)
Study: 12734155
Drug: s-ketamine 1
Normalized name: (S)-(-)-ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: s-ketamine 1 mg.kg(‐1) and midazolam 0.2 mg.kg(‐1) (Group K1)
Study: 12734155
Drug: s-ketamine 2
Normalized name: (S)-(-)-ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: s-ketamine 2 mg.kg(‐1) and midazolam 0.2 mg.kg(‐1) (Group K2)
Study: 12734155
Drug: midazolam 0.2
Normalized name: midazolam 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 0.2 mg.kg(‐1) (Group M)
Study: 10581142
Drug: Intravenous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone 125 mg per hour (total 3 g)
Study: 8564104
Drug: Methacholine inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine inhalation challenges (MIC)
Study: 8394627
Drug: Metronidazole (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (0.4 g b.i.d.)
Study: 6124473
Drug: Sulfasalazine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine (1.5 g b.i.d.)
Study: 25239849
Drug: Cholecalciferol (VD3)
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (VD3) supplementation (200,000 IU IM quarterly) and daily oral calcium (Ca) for 12 months (Group D)
Study: 23663206
Drug: Topical lidocaine/prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine/prilocaine
Study: 21303366
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of brochure and video
Study: 19196529
Drug: Anamorelin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anamorelin (25 mg daily)
Study: 19196529
Drug: Anamorelin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anamorelin (50 mg daily)
Study: 19196529
Drug: Anamorelin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anamorelin (75 mg daily)
Study: 8154413
Drug: Metoprolol (M)
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol (M) treatment for 72 hours, supplemented with three intraperitoneal doses over the first 24 hours.
Study: 8154413
Drug: Metoprolol (M)
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol (M) treatment
Study: 28052211
Drug: No-F (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-F (no fluoride therapy)
Study: 21632808
Drug: Cotreatment with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotreatment with pegvisomant (15-30 mg twice a week) and SA (half the usual dosage)
Study: 21632808
Drug: SA monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SA monotherapy (unchanged dosage)
Study: 19559191
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg) daily
Study: 19559191
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg) plus aspirin (100 mg) daily
Study: 15226784
Drug: L-arginine (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (9 g/day for 7 days)
Study: 8277768
Drug: Cimetidine alone
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine alone (800 mg twice a day)
Study: 8277768
Drug: Cimetidine with
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine with DMSO (500 mg, four times a day)
Study: 8277768
Drug: Cimetidine with
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine with allopurinol (50 mg, four times a day)
Study: 8277768
Drug: Cimetidine alone
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine alone (800 mg at bedtime)